Articles On Amplia Therapeutics (ASX:ATX)

Title Source Codes Date
Amplia Therapeutics receives $1.14m tax refund for cancer drug development expenses

Clinical development company Amplia Therapeutics (ASX: ATX) has received a research and development tax incentive refund from the federal government for expenditure related to advancing its focal adhesion kinase (FAK) inhibitors for cancer...

SmallCaps ATX 6 days ago
Amplia Therapeutics receives million dollar Research and Development Tax Incentive Refund

The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.

Proactive Investors ATX 6 days ago
Amplia Therapeutics says Garvan paper has increased its confidence in upcoming Phase 2 trial

Proactive Investors ATX 2 weeks ago
Amplia Therapeutics appoints Bio101’s Hamish George as chief financial officer

George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years. 

Proactive Investors ATX 2 weeks ago
Amplia Therapeutics discusses candidates for cancer and fibrotic diseases treatment

Proactive Investors ATX 2 weeks ago
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer

New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned Phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prio...

SmallCaps ATX 2 weeks ago
Amplia Therapeutics welcomes Garvan paper highlighting benefits of FAK inhibition in pancreatic cancer models

FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.

Proactive Investors ATX 2 weeks ago
New paper describes biology of Amplia's FAK inhibitor

Amplia Therapeutics (ASX:ATX), which is developing new drugs for the treatment of cancer and fibrosis, has announced the publication of a paper from the Garvan Institute of Medical Research.

BiotechDispatch ATX 2 weeks ago
Amplia Therapeutics and Patrys outline unique cancer drugs at Proactive Lifesciences Webinar

Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.

Proactive Investors ATX 3 weeks ago
Closing Bell: ASX defies the odds to finish in positive territory

The ASX was set for another negative day if futures and Wall Street’s drop were any guide — but even with a bad start, Australia’s bourse finished in the green. The ASX 200 fell as much as 0.50% in the first few minutes of trade but closed...

Stockhead ATX 4 weeks ago
Amplia Therapeutics shifts from pre-clinical to drug development with two potent candidates for cancer and fibrotic diseases treatment

It is developing two proprietary, orally available, small molecule Focal Adhesion Kinase inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases.

Proactive Investors ATX 4 weeks ago
Amplia Therapeutics details upcoming Phase 2 pancreatic cancer trial

Proactive Investors ATX 1 month ago
Amplia Therapeutics to conduct Phase 2 trial for Focal Adhesion Kinase inhibitor AMP945 in first line pancreatic cancer patients

The pharmaceutical company plans to initiate patient recruitment at Australian sites in the first quarter of 2022.

Proactive Investors ATX 1 month ago
Miners fuel ASX fall at open, BHP, RIO, FMG trading in red 

Highlights The ASX 200 fell 18.7 points or 0.25% to 7,418.6 in the opening session, while the ASX All ordinaries index was 0.24% down at 7,722.1.   The market breadth is extremely weak so far today, with 10 out of the 11 sectors trad...

Kalkine Media ATX 1 month ago
ASX Health Stocks: Amplia begins Phase 2 trial for pancreatic cancer, while Avecho commences Phase 1 of cannabis gel

The ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the broader ASX 200 index which fell by 0.70%. The cancer and fibrosis focused company, Amplia Therapeutics (ASX:ATX), has completed the design fo...

Stockhead ATX 1 month ago
Amplia Therapeutics completes design of Phase 2 AMP945 trial to treat advanced pancreatic cancer

Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a Phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced pancreatic cancer. The design is based...

SmallCaps ATX 1 month ago
Directors’ Trades: Otto Buttula buys another $580k of Rhythm Biosciences shares

Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi...

Stockhead ATX 1 month ago
Closing Bell: A red-hot IPO, possible pump and dump, and the Big Australian goes ex-divvie

The ASX 200 finished in the red today, as the big end of town played second fiddle to the microcap Emerging Companies index which posted a solid ~0.7% gain. Mining stocks dragged on the broader index, as BHP (ASX:BHP) traded ex-dividend (it...

Stockhead ATX 1 month ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead ATX 1 month ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead ATX 2 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead ATX 2 months ago
Amplia Therapeutics prepares for phase two AMP945 trial backed by shareholders

Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis (IPF) patients. This work is being suppo...

SmallCaps ATX 2 months ago
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis. The results confirmed the company’s prelimi...

SmallCaps ATX 2 months ago
Market Highlights and 5 ASX Small Caps to watch on Wednesday

Wall Street, European stocks rebound on the dip All three US benchmarks rallied overnight, along with the European sharemarkets as investors bought the dip. The Dow Jones rose 1.62%, S&P 500 by 1.52%, while the Nasdaq rose by 1.57%. The...

Stockhead ATX 2 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead ATX 2 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead ATX 3 months ago
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat patients with pancreatic cancer. The Melbo...

SmallCaps ATX 3 months ago
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment

Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Proactive Investors ATX 3 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead ATX 4 months ago
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead ATX 4 months ago
Why the Amplia (ASX:ATX) share price is rocketing 41% higher today

The Amplia Therapeutics Ltd (ASX: ATX) share price is one of the best performers on the ASX today. This comes after the pharmaceutical company announced positive news in trials to improve pancreatic cancer survival. At one point in intrada...

Motley Fool ATX 4 months ago
Five penny stocks packing a punch today

Summary Amplia Therapeutics has received promising data from its Focal Adhesion Kinase inhibitor in the treatment of cancer. Spectur expects to post a record revenue of approximately AU$1.8 million in Q4. Douugh has formed a strategic...

Kalkine Media ATX 4 months ago
Positive clinical data sends Amplia Therapeutics nearly 50 per cent up

Biotech Amplia Therapeutics (ASX:ATX) was one of this morning’s biggest winners after positive clinical data. The company has a drug fighting cancer, AMP945, that inhibits Focal Adhesion Kinase (FAK). FAK is a protein that is over-expressed...

Stockhead ATX 4 months ago
10 at 10: These ASX stocks have risen to the skies this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead ATX 4 months ago
Amplia Therapeutics updates on data from cancer collaboration

Amplia Therapeutics (ASX:ATX) says it has received new data from its collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research in Sydney.

BiotechDispatch ATX 4 months ago
Invion led a group of ASX cancer stocks up after promising news

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead ATX 4 months ago
ScoPo’s Powerplays: Health sector trades sideways but M&A plays coloured the week

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Stockhead ATX 5 months ago
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr...

Stockhead ATX 5 months ago
Last Orders: The ASX starts the week slightly higher

After gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The ASX 200 closed at 7,029 points, which was 0.04 per cent higher than Friday. Small caps had a worse day – the ASX Emerging Companies Index clos...

Stockhead ATX 5 months ago
Last Orders: Despite losing week, best month in six for small caps

Small caps have declined for the fourth time in the past five days — but still finished April with their strongest performance in six months. The Small Ordinaries index gained 4.83 per cent in April despite declining 0.96 per cent this week...

Stockhead ATX 5 months ago
Here’s why ASX healthcare shares OCC and ADO were trending today

Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou...

Kalkine Media ATX 5 months ago
Respiri (ASX:RSH) shares flying high on TerryWhite Chemmart partnership

Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,...

Kalkine Media ATX 5 months ago
Why were Australian healthcare shares EX1 and RAC trending today?

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Kalkine Media ATX 6 months ago
Why are Amplia Therapeutics (ASX:ATX) shares flying high today?

Summary Amplia Therapeutics has obtained data from an animal study demonstrating its FAK inhibitors lower fibrosis arising from the NASH. The positive data from the animal study is anticipated to support the future development and part...

Kalkine Media ATX 6 months ago
10 at 10: These ASX stocks have made surprising growth this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead ATX 6 months ago
Why are Australian MedTech penny shares TTB and UBI trending today?

Source: REDPIXEL.PL, Shutterstock Summary Total Brain introduced discrete & continuous HRV functionality to its existing mental health self-monitoring and self-care platform. Electrochemical strips developer Universal Biosensors I...

Kalkine Media ATX 6 months ago
Amplia completes dosing in phase one study of AMP945

Amplia Therapeutics (ASX:ATX), a company developing new drugs for the treatment for cancer and fibrosis, has announced it has successfully completed the dosing of subjects in its phase one clinical trial of its focal adhesion kinase...

BiotechDispatch ATX 6 months ago
Market highlights and 5 ASX small caps to watch on Thursday

Wall Street at record highs again after Fed speech US stocks rose to record highs again after the US Federal Reserve decided to keep rates at near zero until 2023. Fed chairman Jerome Powell said that he expected growth for 2020 to be 6.5 p...

Stockhead ATX 7 months ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead ATX 7 months ago
Three ASX penny stocks in the healthcare space – OCC, ATX and EMD

Source: Guschenkova, Shutterstock Summary Amid the detrimental impact of the ongoing pandemic, the healthcare sector has continued to witness new heights. Penny stocks are grabbing attention from market participants as they are low-pr...

Kalkine Media ATX 7 months ago